Benchmark analyst Bill Sutherland lowered the firm’s price target on Quipt Home Medical (QIPT) to $4 from $6 and keeps a Buy rating on the shares after revenue missed expectations in fiscal Q2. On a positive note, Quipt continues to see no negative impact from GLP-1 medications on demand for sleep therapy set ups and supplies, like other respiratory-focused home medical equipment companies, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QIPT:
- Quipt Home Medical: Resilience and Growth Potential Amidst Challenges
- Quipt Home Medical downgraded to Hold from Buy at Canaccord (yesterday)
- Quipt Home Medical downgraded to Hold from Buy at Canaccord
- Quipt Home Medical: Strategic Initiatives and Financial Resilience Amidst Revenue Challenges
- Quipt Home Medical Reports Q2 2025 Results Amid Revenue Challenges